JuNeng Technology Limited (NENG)

Oncternal Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Year Ending	Mar 31, 2025	Mar 31, 2024
Cash & Equivalents	1.55	0.05
Cash & Cash Equivalents	1.55	0.05
Cash Growth	2772.39%	-
Receivables	0.44	0.02
Other Current Assets	1.98	1.18
Total Current Assets	3.97	1.25
Property, Plant & Equipment	-	0
Goodwill and Intangibles	0.07	-
Total Long-Term Assets	0.07	0
Total Assets	4.04	1.25
Accounts Payable	0	-
Deferred Revenue	0.09	0.05
Current Debt	0.39	0.34
Other Current Liabilities	0.33	0.03
Total Current Liabilities	0.81	0.42
Total Liabilities	0.81	0.42
Total Debt	0.39	0.34
Debt Growth	16.24%	-
Retained Earnings	1.26	0.43
Comprehensive Income	-0.04	-0.02
Shareholders' Equity	3.23	0.83
Net Cash (Debt)	1.16	-0.28
Working Capital	3.16	0.83

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).